MX2019004767A - Composiciones dispersables. - Google Patents

Composiciones dispersables.

Info

Publication number
MX2019004767A
MX2019004767A MX2019004767A MX2019004767A MX2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A MX 2019004767 A MX2019004767 A MX 2019004767A
Authority
MX
Mexico
Prior art keywords
compositions
useful
dispersible compositions
dispersible
rilpivirine
Prior art date
Application number
MX2019004767A
Other languages
English (en)
Inventor
Patankar Harshad
Martha Felix Goyvaerts Nicolaas
Rajan Ranga Rajan Gopal
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2019004767A publication Critical patent/MX2019004767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones dispersables que comprenden rilpivirina o una sal de adición de ácido farmacéuticamente aceptable del mismo como principio activo; dichas composiciones son útiles en el tratamiento de la infección por VIH 5 y sus propiedades de dispersabilidad las hacen particularmente útiles entre la población pediátrica o geriátrica.
MX2019004767A 2016-10-24 2017-10-23 Composiciones dispersables. MX2019004767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Publications (1)

Publication Number Publication Date
MX2019004767A true MX2019004767A (es) 2019-07-01

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004767A MX2019004767A (es) 2016-10-24 2017-10-23 Composiciones dispersables.

Country Status (22)

Country Link
US (2) US11065198B2 (es)
EP (2) EP4248947A3 (es)
JP (2) JP7197474B2 (es)
KR (2) KR20240011873A (es)
CN (1) CN110191704A (es)
BR (1) BR112019007564A2 (es)
CA (1) CA3039562A1 (es)
DK (1) DK3528791T3 (es)
ES (1) ES2970870T3 (es)
FI (1) FI3528791T3 (es)
HR (1) HRP20240118T1 (es)
HU (1) HUE064823T2 (es)
LT (1) LT3528791T (es)
MA (1) MA46563B1 (es)
MX (1) MX2019004767A (es)
PL (1) PL3528791T3 (es)
PT (1) PT3528791T (es)
RS (1) RS65159B1 (es)
RU (1) RU2019115672A (es)
SI (1) SI3528791T1 (es)
TW (1) TWI821163B (es)
WO (1) WO2018077815A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065121A4 (en) 2019-11-29 2023-11-29 Aptorum Therapeutics Limited COMPOSITION COMPRISING RILPIVIRINE AND ITS USE FOR THE TREATMENT OF TUMORS OR CANCER
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN102225902B (zh) 2002-08-09 2013-04-24 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
PL2040671T3 (pl) 2006-06-23 2018-08-31 Janssen Sciences Ireland Uc Wodne zawiesiny TMC278
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
CA2949094A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Also Published As

Publication number Publication date
EP4248947A3 (en) 2023-11-22
EP3528791B1 (en) 2023-12-06
HUE064823T2 (hu) 2024-04-28
US20220008333A1 (en) 2022-01-13
CN110191704A (zh) 2019-08-30
FI3528791T3 (fi) 2024-01-30
WO2018077815A1 (en) 2018-05-03
KR20190073450A (ko) 2019-06-26
MA46563A (fr) 2019-08-28
ES2970870T3 (es) 2024-05-31
SI3528791T1 (sl) 2024-04-30
HRP20240118T1 (hr) 2024-04-12
PL3528791T3 (pl) 2024-04-02
JP7197474B2 (ja) 2022-12-27
RU2019115672A (ru) 2020-11-24
LT3528791T (lt) 2024-05-27
DK3528791T3 (da) 2024-01-29
TW201828927A (zh) 2018-08-16
US20200069579A1 (en) 2020-03-05
CA3039562A1 (en) 2018-05-03
TWI821163B (zh) 2023-11-11
BR112019007564A2 (pt) 2019-07-02
JP2020500168A (ja) 2020-01-09
KR20240011873A (ko) 2024-01-26
US11065198B2 (en) 2021-07-20
EP3528791A1 (en) 2019-08-28
MA46563B1 (fr) 2024-01-31
RS65159B1 (sr) 2024-02-29
EP4248947A2 (en) 2023-09-27
PT3528791T (pt) 2024-02-19
RU2019115672A3 (es) 2021-01-21
JP2023011659A (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
PH12017501331A1 (en) Dispersible compositions
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
AU2018285213A1 (en) Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides
EP3407918A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
NZ733174A (en) Quinazoline derivatives used to treat hiv
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
PH12016500389B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3757105A3 (en) Polycyclic pyridone derivative having integrase inhibitory activity
UA114006C2 (xx) Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл
MX2019004767A (es) Composiciones dispersables.
WO2017211371A3 (en) Calr and jak2 vaccine compositions
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
MX2017015293A (es) Composicion para tratar lesiones tisulares.
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
WO2015086738A3 (en) Hiv vaccine
MA40496A (fr) Capsacinoïdes et leurs utilisations en tant que médicaments
MX2019004375A (es) Inhibidores de bromodominios.
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
WO2017142368A3 (ko) 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물
PH12019501206A1 (en) Medical skin external preparation
WO2019212427A3 (en) Compositions comprising erdosteine and ascorbic acid
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
TR201714726A1 (tr) Antikolinerjik bir etken madde içeren farmasötik formülasyon.
WO2016112339A8 (en) Stable formulations for the oral administration of amphotericin b and related methods